Public filings / SPRY on Yahoo Finance (opens in a new tab)
SPRY: insider buying, 13F holders, analyst moves
ARS Pharmaceuticals Inc - US
A summary of public filings about ARS Pharmaceuticals Inc - US. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
5 of our 100 managers hold SPRY
Combined reported value $223.9M.
Holders among our 100 managers: 4 in Q3 2023, 5 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| RA Capital | $87.0M | 0.76% | Unchanged |
| Rubric Capital | $68.4M | 0.63% | Added |
| Deerfield Company | $60.1M | 0.63% | Unchanged |
| Third Point | $8.0M | 0.17% | Unchanged |
| Tudor Investment | $368K | 0.00% | New |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.